Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 4/20 | 0.57 |
| ▸ | GSK3B | P49841 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HPGDS | O60760 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ELANE | P08246 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8740774 | 1.00 | PTPN1 (0.57) | PTPN1GSK3BALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL29758522 | 1.00 | PTPN1 (0.57) | PTPN1GSK3BALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL9409754 | 0.85 | PTPN1 (0.65) | PTPN1GSK3BALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL28053559 | 0.84 | ALDH1A1 (0.53) | ALDH1A1HPGDSMN1; SMN2HSD17B10KDM4E | |
| SCHEMBL15979732 | 0.84 | ALDH1A1 (0.53) | ALDH1A1HPGDSMN1; SMN2HSD17B10KDM4E | |
| SCHEMBL30089542 | 0.84 | ALDH1A1 (0.53) | ALDH1A1HPGDSMN1; SMN2HSD17B10KDM4E | |
| SCHEMBL3703924 | 0.82 | ALDH1A1 (0.51) | ALDH1A1HPGDSMN1; SMN2HSD17B10KDM4E | |
| SCHEMBL29322296 | 0.81 | PTPN1 (0.52) | PTPN1GSK3BALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL8744733 | 0.80 | ALDH1A1 (0.50) | ALDH1A1HPGDSMN1; SMN2HSD17B10KDM4E | |
| SCHEMBL12430466 | 0.80 | ALDH1A1 (0.50) | ALDH1A1HPGDSMN1; SMN2HSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 769 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4651946-B2 | — | — | 2011-03-16 | — | — | JP | claimed |
| US-20090202439-A1 | Methods for treatment of angiogenesis | THE JOHNS HOPKINS UNIVERSITY (US) | 2009-08-13 | — | — | US | claimed |
| EP-1799258-A4 | METHODS FOR TREATMENT OF ANGIOGENESIS | UNIV JOHNS HOPKINS (US) | 2009-07-22 | — | — | EP | claimed |
| EP-1951315-A2 | PHOSPHOLIPASE INHIBITORS, INCLUDING MULTI-VALENT PHOSPHOLIPASE INHIBITORS, AND USE THEREOF, INCLUDING AS LUMEN-LOCALIZED PHOSPHOLIPASE INHIBITORS | Ilypsa, Inc. (US) | 2008-08-06 | — | — | EP | claimed |
| EP-1558273-A4 | TREATMENT AND PREVENTION OF PULMONARY CONDITIONS | SCRIPPS RESEARCH INST (US) | 2008-07-16 | — | — | EP | claimed |
| EP-1747003-A4 | PHOSPHOLIPASE INHIBITORS LOCALIZED IN THE GASTROINTESTINAL LUMEN | ILYPSA INC (US) | 2008-01-09 | — | — | EP | claimed |
| US-20070292385-A1 | Phospholipase Inhibitors Localized in the Gastrointestinal Lumen | ILYPSA, INC. | 2007-12-20 | — | — | US | claimed |
| EP-1799258-A2 | METHODS FOR TREATMENT OF ANGIOGENESIS | THE JOHNS-HOPKINS UNIVERSITY (US) | 2007-06-27 | — | — | EP | claimed |
| WO-2007056279-A2 | PHOSPHOLIPASE INHIBITORS, INCLUDING MULTI-VALENT PHOSPHOLIPASE INHIBITORS, AND USE THEREOF, INCLUDING AS LUMEN-LOCALIZED PHOSPHOLIPASE INHIBITORS | ILYPSA, INC. (US) | 2007-05-18 | — | — | WO | claimed |
| EP-1747003-A1 | PHOSPHOLIPASE INHIBITORS LOCALIZED IN THE GASTROINTESTINAL LUMEN | Ilypsa, Inc. (US) | 2007-01-31 | — | — | EP | claimed |
| WO-2003051295-A2 | NEUTRALIZATION OF STRATUM CORNEUM TO TREAT HYPERKERATOTIC SKIN LESIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2003-06-26 | — | — | WO | claimed |
| US-20030113352-A1 | Neutralization of stratum corneum to treat hyperkeratotic skin lesions | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2003-06-19 | — | — | US | claimed |
| US-6562606-B1 | Composition for use as tool in the transfer pharmeceutical across epithelial barriers | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2003-05-13 | — | — | US | claimed |
| US-6190894-B1 | APPLYING INHIBITORS OF BIOSYNTHESIS OR DEGRADATION, DEGRADATION ENZYMES, AND/OR INHIBITORS AND ACTIVATORS OF METABOLIC ENZYMES; FOR TOPICAL ADMINISTRATION OF PHYSIOLOGICALLY ACTIVE SUBSTANCES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2001-02-20 | — | — | US | claimed |
| WO-1998017253-A1 | METHOD AND COMPOSITIONS FOR DISRUPTING THE EPITHELIAL BARRIER FUNCTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1998-04-30 | — | — | WO | claimed |
| EP-0764017-A4 | METHODS AND COMPOSITIONS FOR DISRUPTING THE EPITHELIAL BARRIER FUNCTION | CELLEGY PHARMA INC (US) | 1997-08-06 | — | — | EP | claimed |
| EP-0764017-A1 | METHODS AND COMPOSITIONS FOR DISRUPTING THE EPITHELIAL BARRIER FUNCTION | CELLEGY PHARMACEUTICALS, INC. (US) | 1997-03-26 | — | — | EP | claimed |
| WO-1994021230-A1 | METHOD AND COMPOSITIONS FOR DISRUPTING THE EPITHELIAL BARRIER FUNCTION | CELLEGY PHARMACEUTICALS, INC. (US) | 1994-09-29 | — | — | WO | claimed |
| WO-1993019745-A1 | METHOD OF TREATING CLOSTRIDIUM DIFFICILE COLITIS AND CHOLERA | THE UNIVERSITY OF VIRGINIA PATENTS FOUNDATION (US) | 1993-10-14 | — | — | WO | claimed |
| EP-0322262-B1 | BASIC PROTEIN PHOSPHOLIPASE A2 OF AN ELAPIDE SNAKE VENOM, AMINO ACID SEQUENCE THEREOF, DERIVATIVES AND FRAGMENTS THEREOF, PROCESS FOR OBTAINING THEM, THERAPEUTIC COMPOSITIONS AND DIAGNOSTIC AGENTS CONTAINING THEM | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 1993-01-13 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090202439-A1 | Methods for treatment of angiogenesis | B4GALT1, FLT1, FLT4 | PTPN1 3288/4885GSK3B 1968/4885ALDH1A1 999/4885 |
| US-20070292385-A1 | Phospholipase Inhibitors Localized in the Gastrointestinal Lumen | PNLIP, PLA2G2E, PLA2G4B | PTPN1 1271/4885GSK3B 2515/4885ALDH1A1 3621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.